17,800 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bought by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 17,800 shares of the biotechnology company's stock, valued at approximately $2,164,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SRPT. Charles Schwab Investment Management Inc. increased its holdings in Sarepta Therapeutics by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock valued at $75,842,000 after buying an additional 12,000 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after acquiring an additional 44,306 shares during the period. Proficio Capital Partners LLC purchased a new position in Sarepta Therapeutics in the 4th quarter valued at approximately $3,829,000. Summit Partners Public Asset Management LLC raised its holdings in Sarepta Therapeutics by 547.9% during the third quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company's stock worth $17,250,000 after purchasing an additional 116,800 shares during the last quarter. Finally, Nordea Investment Management AB boosted its position in Sarepta Therapeutics by 19.1% during the fourth quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company's stock worth $8,228,000 after purchasing an additional 10,815 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Remove Ads

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Trading Down 3.0 %

Shares of SRPT traded down $1.91 during mid-day trading on Tuesday, reaching $61.91. The company had a trading volume of 3,548,801 shares, compared to its average volume of 1,280,835. Sarepta Therapeutics, Inc. has a fifty-two week low of $61.56 and a fifty-two week high of $173.25. The firm has a fifty day simple moving average of $100.47 and a 200-day simple moving average of $115.03. The stock has a market cap of $6.01 billion, a price-to-earnings ratio of 49.53 and a beta of 0.79. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SRPT. Scotiabank dropped their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research report on Thursday, March 20th. Royal Bank of Canada downgraded shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their target price for the company from $161.00 to $87.00 in a report on Monday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Needham & Company LLC reissued a "buy" rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research report on Wednesday, March 19th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $164.05.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.